ES2894257T3 - Epítopos restringidos por MHC-E, moléculas de unión y métodos y usos relacionados - Google Patents

Epítopos restringidos por MHC-E, moléculas de unión y métodos y usos relacionados Download PDF

Info

Publication number
ES2894257T3
ES2894257T3 ES17740170T ES17740170T ES2894257T3 ES 2894257 T3 ES2894257 T3 ES 2894257T3 ES 17740170 T ES17740170 T ES 17740170T ES 17740170 T ES17740170 T ES 17740170T ES 2894257 T3 ES2894257 T3 ES 2894257T3
Authority
ES
Spain
Prior art keywords
cases
mhc
peptide
molecule
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17740170T
Other languages
English (en)
Spanish (es)
Inventor
Semih Tareen
James Sissons
Mark Frohlich
Allen Ebens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juno Therapeutics Inc
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Application granted granted Critical
Publication of ES2894257T3 publication Critical patent/ES2894257T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES17740170T 2016-06-27 2017-06-27 Epítopos restringidos por MHC-E, moléculas de unión y métodos y usos relacionados Active ES2894257T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662355236P 2016-06-27 2016-06-27
PCT/US2017/039593 WO2018005556A1 (en) 2016-06-27 2017-06-27 Mhc-e restricted epitopes, binding molecules and related methods and uses

Publications (1)

Publication Number Publication Date
ES2894257T3 true ES2894257T3 (es) 2022-02-14

Family

ID=59351076

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17740170T Active ES2894257T3 (es) 2016-06-27 2017-06-27 Epítopos restringidos por MHC-E, moléculas de unión y métodos y usos relacionados

Country Status (8)

Country Link
US (1) US20190324030A1 (enExample)
EP (2) EP3475706B1 (enExample)
JP (2) JP7054397B2 (enExample)
CN (1) CN109937364B (enExample)
CA (1) CA3027999A1 (enExample)
ES (1) ES2894257T3 (enExample)
MA (1) MA45491A (enExample)
WO (1) WO2018005556A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110809580A (zh) * 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
JP7181517B2 (ja) 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
AU2019309948A1 (en) * 2018-07-23 2021-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
EP3896158A4 (en) * 2018-12-11 2022-11-02 Kyoto University METHODS OF INDUCING A DELETION IN GENOMIC DNA
CN109913414A (zh) * 2019-03-21 2019-06-21 吉林省银丰生物工程技术有限公司 肝癌afp特异性人工抗原递呈细胞诱导试剂盒
MX2021012004A (es) * 2019-03-30 2021-11-04 Biontech Us Inc Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas.
TW202115245A (zh) 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
UY38800A (es) * 2019-07-26 2021-01-29 Janssen Biotech Inc Receptor de antígeno quimérico (car) anti-hk2
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
JP7670358B2 (ja) * 2020-01-02 2025-04-30 寧波茂行生物医薬科技有限公司 修飾された免疫エフェクター細胞及びその調製方法
CN111116716B (zh) * 2020-03-03 2022-03-01 中国医科大学 一种与骨髓瘤细胞高表达抗原hla-e特异性结合的多肽及其用途
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) * 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
WO2022047325A1 (en) * 2020-08-31 2022-03-03 The Trustees Of Columbia University In The City Of New York Targeting of tgm4 to treat prostate cancer
WO2022129472A1 (en) 2020-12-18 2022-06-23 Novo Nordisk A/S Safe immuno-stealth cells
WO2022136215A1 (en) 2020-12-21 2022-06-30 Novo Nordisk A/S Safe immuno-stealth cells
US20240200031A1 (en) * 2021-04-12 2024-06-20 Memorial Sloan Kettering Cancer Center Engineered hla molecules useful for t cell and nk cell activation and expansion
WO2023156903A1 (en) * 2022-02-19 2023-08-24 Waters Technologies Corporation Novel size exclusion chromatography column technologies for analysis of crispr molecules
WO2024036303A2 (en) * 2022-08-11 2024-02-15 The Trustees Of The University Of Pennsylvania Universal t cells and compositions and methods of use thereof
CN117976074B (zh) * 2024-03-29 2024-06-25 北京悦康科创医药科技股份有限公司 Mhc分子和抗原表位亲和力确定方法、模型训练方法及装置

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983001A (en) 1972-05-10 1976-09-28 Ceskoslovenska Akademie Ved Isolation of biologically active compounds by affinity chromatography
US4213860A (en) 1976-06-30 1980-07-22 Board of Regents, State of Florida for and on behalf of the University of Florida Affinity chromatography and substrate useful therefor
GB1602432A (en) 1976-12-15 1981-11-11 Atomic Energy Authority Uk Affinity chromatography
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4175182A (en) 1978-07-03 1979-11-20 Research Corporation Separation of high-activity heparin by affinity chromatography on supported protamine
US4431546A (en) 1981-04-27 1984-02-14 The Public Health Laboratory Services Board Affinity chromatography using metal ions
DE3271828D1 (en) 1981-04-27 1986-07-31 Health Lab Service Board High pressure liquid affinity chromatography
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5821058A (en) 1984-01-16 1998-10-13 California Institute Of Technology Automated DNA sequencing technique
US5171534A (en) 1984-01-16 1992-12-15 California Institute Of Technology Automated DNA sequencing technique
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4811218A (en) 1986-06-02 1989-03-07 Applied Biosystems, Inc. Real time scanning electrophoresis apparatus for DNA sequencing
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5149625A (en) 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
SE8801070D0 (sv) 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4962020A (en) 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5043062A (en) 1989-02-21 1991-08-27 Eastman Kodak Company High performance affinity chromatography column comprising non-porous, nondisperse polymeric packing material
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0527809B1 (en) 1990-04-05 1995-08-16 CREA, Roberto Walk-through mutagenesis
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE4123760C2 (de) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
GB9208733D0 (en) 1992-04-22 1992-06-10 Medical Res Council Dna sequencing method
SG52492A1 (en) 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5374527A (en) 1993-01-21 1994-12-20 Applied Biosystems, Inc. High resolution DNA sequencing method using low viscosity medium
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
EP0682671A4 (en) 1993-02-01 1998-01-14 Seq Ltd METHOD AND DEVICES FOR SEQUENCING DNA.
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
CA2158642A1 (en) 1993-03-19 1994-09-29 Hubert Koster Dna sequencing by mass spectrometry via exonuclease degradation
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6143495A (en) 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
AU728794B2 (en) * 1996-03-05 2001-01-18 Scripps Research Institute, The Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5846727A (en) 1996-06-06 1998-12-08 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Microsystem for rapid DNA sequencing
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
EP0962527B1 (en) 1996-10-17 2004-08-04 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
US5858671A (en) 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US6258533B1 (en) 1996-11-01 2001-07-10 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US5876934A (en) 1996-12-18 1999-03-02 Pharmacia Biotech Inc. DNA sequencing method
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK0971946T3 (da) 1997-01-21 2006-10-30 Gen Hospital Corp Selektion af proteiner ved anvendelse af RNA-protein-fusioner
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
JP2001519143A (ja) 1997-10-02 2001-10-23 スノル・モレキュラー・コーポレーション 可溶性の一本鎖ｔ細胞レセプタータンパク質
BR9910253A (pt) * 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
PT1137812E (pt) 1998-12-02 2007-05-31 Adnexus Therapeutics Inc Fusões adn-proteína e suas utilizações
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6385581B1 (en) 1999-05-05 2002-05-07 Stanley W. Stephenson System and method of providing emotive background sound to text
EP1054018B1 (en) 1999-05-18 2009-01-28 Dyax Corp. Fab fragment libraries and methods for their use
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
IL147037A0 (en) 1999-07-27 2002-08-14 Phylos Inc Peptide acceptor ligation methods
CN1411512A (zh) * 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 嵌合的免疫原性组合物及其编码核酸
US20060035338A1 (en) * 1999-12-17 2006-02-16 Pure Protein Llc Method and apparatus for the production of soluble MHC antigens and uses thereof
AU3095801A (en) * 2000-01-31 2001-08-07 Human Genome Sciences Inc Nucleic acids, proteins, and antibodies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
ES2747357T3 (es) * 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
CN1659436A (zh) 2002-02-28 2005-08-24 英特塞尔股份公司 分离配体的方法
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
CA2568344C (en) 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
JP2008514685A (ja) 2004-10-01 2008-05-08 メディジーン リミテッド 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するｔ細胞レセプター
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
GB0507598D0 (en) * 2005-04-14 2005-05-18 Trojantec Technologies Ltd Composition
WO2006116681A2 (en) * 2005-04-28 2006-11-02 Caprion Pharmaceuticals, Inc. Tat-003 and methods of assessing and treating cancer
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
NZ569535A (en) * 2005-12-30 2011-12-22 Revance Therapeutics Inc Arginine heteromers for topical administration
AU2007235320A1 (en) * 2006-04-05 2007-10-18 The General Hospital Corporation Soluble virus-specific T-cell receptor compositions
CN101663047B (zh) * 2007-02-23 2014-07-09 纽约哥伦比亚大学理事会 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法
WO2008120203A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
PL2856876T3 (pl) 2007-03-30 2018-06-29 Memorial Sloan-Kettering Cancer Center Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
RS53872B2 (sr) * 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010011944A2 (en) 2008-07-25 2010-01-28 Wagner Richard W Protein screeing methods
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
US8465743B2 (en) * 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
SG177025A1 (en) 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
AU2011304728A1 (en) * 2010-09-20 2013-03-14 Biontech Ag Antigen-specific T cell receptors and T cell epitopes
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9880160B2 (en) 2011-03-15 2018-01-30 X-Body, Inc. Antibody screening methods
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
EP2697367B1 (en) * 2011-04-13 2018-12-19 Immunicum AB Method for proliferation of antigen-specific t cells
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CA3114877C (en) * 2011-09-15 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
CN102399265B (zh) * 2011-10-28 2014-06-25 中国人民解放军第四军医大学 Htnv-np 特异性的ctl 表位肽及其应用
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
US10656156B2 (en) * 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014009348A1 (en) * 2012-07-10 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a cytomegalovirus infection in a transplanted patient is suceptible to induce allograft rejection
EP2877489A4 (en) 2012-07-27 2016-04-13 Univ Illinois MANIPULATION OF T-CELL RECEPTORS
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
LT2958943T (lt) * 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
SI2964769T1 (sl) * 2013-03-05 2018-12-31 Oregon Health & Sccience University Citomegalovirusni vektorji, ki omogočajo krmiljenje ciljanja T-celic
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CN103421118B (zh) * 2013-07-16 2015-03-25 中国人民解放军第四军医大学 HTNV-Gn/Gc特异性CTL表位肽及其聚合物和应用
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3071594A4 (en) * 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
CN104163862B (zh) * 2013-12-04 2017-02-08 魏敏杰 与人mhc‑i类分子结合的grp78多肽表位
CN103933560B (zh) * 2013-12-09 2017-04-12 安徽农业大学 一种应用Ii‑Key活性四肽携带法氏囊VP2和新城疫HN抗原肽表位嵌合疫苗的制备方法
US10654907B2 (en) * 2014-01-29 2020-05-19 University Health Network Methods and compositions for producing a cell expressing a T cell receptor
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2017161092A1 (en) * 2016-03-16 2017-09-21 Neximmune, Inc. Production of antigen-specific t-cells
JP2021501180A (ja) * 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用

Also Published As

Publication number Publication date
EP3475706A1 (en) 2019-05-01
MA45491A (fr) 2019-05-01
US20190324030A1 (en) 2019-10-24
JP2022081490A (ja) 2022-05-31
WO2018005556A1 (en) 2018-01-04
EP3992632A1 (en) 2022-05-04
CA3027999A1 (en) 2018-01-04
CN109937364B (zh) 2022-12-02
JP2019520591A (ja) 2019-07-18
EP3475706B1 (en) 2021-08-11
CN109937364A (zh) 2019-06-25
JP7340638B2 (ja) 2023-09-07
JP7054397B2 (ja) 2022-04-13

Similar Documents

Publication Publication Date Title
JP7340638B2 (ja) Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
JP6987134B2 (ja) ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
US12383601B2 (en) Chimeric antigen receptors and uses thereof
AU2019331496B2 (en) Methods of making chimeric antigen receptor-expressing cells
US10786533B2 (en) Engineered cells for adoptive cell therapy
JP2022091750A (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
EP4110376A2 (en) Methods of making chimeric antigen receptor-expressing cells
AU2021225949A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2021513839A (ja) 改変された多能性幹細胞並びに製造方法及び使用方法
AU2025283489A1 (en) Phenotypic markers for cell therapy and related methods
JP2021533746A (ja) 操作された細胞およびその組成物を生成するための方法
CN116249769A (zh) 功能增强的免疫细胞
HK40074466A (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
RU2841244C2 (ru) Химерные антигенные рецепторы и пути их применения
HK40007215A (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
HK40007215B (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
HK40095241A (zh) 功能增强的免疫细胞